These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23140299)

  • 1. Androgen receptor in human health: a potential therapeutic target.
    Siddique HR; Nanda S; Parray A; Saleem M
    Curr Drug Targets; 2012 Dec; 13(14):1907-16. PubMed ID: 23140299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
    Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
    FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen action and metabolism in prostate cancer.
    Green SM; Mostaghel EA; Nelson PS
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):3-13. PubMed ID: 22453214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
    Isaacsson Velho P; Carducci MA
    Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in androgen receptor targeted therapy for prostate cancer.
    Ahmed A; Ali S; Sarkar FH
    J Cell Physiol; 2014 Mar; 229(3):271-6. PubMed ID: 24037862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor as a therapeutic target.
    Gao W
    Adv Drug Deliv Rev; 2010 Oct; 62(13):1277-84. PubMed ID: 20708648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
    Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
    Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
    Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
    Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
    Antonarakis ES; Armstrong AJ; Dehm SM; Luo J
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):231-41. PubMed ID: 27184811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.
    Zhu W; Zhu DS; Madan RA; Gulley JL; Figg WD; Dahut WL
    Am J Ther; 2010; 17(2):176-81. PubMed ID: 20019584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.
    Desiniotis A; Schäfer G; Klocker H; Eder IE
    Int J Cancer; 2010 Feb; 126(3):775-89. PubMed ID: 19653278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence.
    Libertini SJ; Tepper CG; Rodriguez V; Asmuth DM; Kung HJ; Mudryj M
    Cancer Res; 2007 Oct; 67(19):9001-5. PubMed ID: 17909000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel class of pyranocoumarin anti-androgen receptor signaling compounds.
    Guo J; Jiang C; Wang Z; Lee HJ; Hu H; Malewicz B; Lee HJ; Lee JH; Baek NI; Jeong JH; Kim DK; Kang KS; Kim SH; Lu J
    Mol Cancer Ther; 2007 Mar; 6(3):907-17. PubMed ID: 17363485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
    Knudsen KE; Scher HI
    Clin Cancer Res; 2009 Aug; 15(15):4792-8. PubMed ID: 19638458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
    Yang JC; Ok JH; Busby JE; Borowsky AD; Kung HJ; Evans CP
    Cancer Res; 2009 Jan; 69(1):151-60. PubMed ID: 19117998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.